Skip to main content
HighlightsHighlights Archive

New partner joins the Innovative Licensing and Access Pathway (ILAP)

By October 6, 2021No Comments

A new partner has been announced as part of the Innovative Licensing and Access Pathway (ILAP). The ILAP will be joined by All Wales Therapeutics and Toxicology Centre (AWTTC) as an established partner. The other partners include: Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC).

The Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines, according to the Government. These medicines include new chemical entities, biological medicines, new indications and repurposed medicines. Commercial and non-commercial medicine developers are invited to take part in the Pathway.

The first step in the Pathway revolves around the Innovation Passport application, and leads to the creation of a product-specific Target Development Profile. The TDP will “define key regulatory and development features, identify potential pitfalls and create a road map for delivering early patient access”.

The Innovation Passport fee stands at £3,624, and Initial Target Development Profile (TDP) fee at £4,451. The ILAP also supports Project Orbis, a programme coordinated by the US Food and Drug Administration (FDA), that seeks to review approve promising cancer treatments across the globe.

According to NICE, the ILAP is an opportunity to rethink and practice different methods following the UK’s departure from the European Union and will benefit patients, the life science sector and the NHS.